Camilla H. Heinio
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Journal: Oncoimmunology
Published: August 07, 2023
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Journal: Frontiers in immunology
Published: February 21, 2023
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Journal: Frontiers in immunology
Published: October 03, 2022
Oncolytic adenovirus for treatment of malignant ascites.
Journal: Molecular therapy oncolytics
Published: August 29, 2022
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
Journal: Oncoimmunology
Published: July 18, 2022
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
Journal: Molecular therapy oncolytics
Published: July 15, 2022
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.
Journal: Diseases (Basel, Switzerland)
Published: May 19, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
Journal: Oncoimmunology
Published: January 27, 2022
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Journal: Frontiers in immunology
Published: October 13, 2021
Last Updated: 09/26/2026